Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 206,238 shares, an increase of 278.5% from the January 15th total of 54,493 shares. Based on an average daily trading volume, of 296,509 shares, the days-to-cover ratio is currently 0.7 days. Currently, 6.1% of the company’s shares are short sold. Currently, 6.1% of the company’s shares are short sold. Based on an average daily trading volume, of 296,509 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Capstone Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors bought a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned about 0.40% of Capstone Therapeutics at the end of the most recent quarter. 2.55% of the stock is owned by institutional investors.

Capstone Therapeutics Stock Up 6.5%

Shares of Capstone Therapeutics stock opened at $0.58 on Wednesday. Capstone Therapeutics has a 1 year low of $0.49 and a 1 year high of $4.18. The firm has a market cap of $4.80 million, a price-to-earnings ratio of -0.61 and a beta of -1.21. The company has a 50-day moving average of $0.71 and a 200 day moving average of $1.01. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35.

Capstone Therapeutics (NASDAQ:CAPS) last posted its quarterly earnings data on Tuesday, November 18th. The company reported ($0.35) EPS for the quarter. Capstone Therapeutics had a negative return on equity of 29.50% and a negative net margin of 12.40%.The business had revenue of $13.65 million for the quarter.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.